Consistently, ganetespib could also significantly augment FBXL2-mediated suppression of cell proliferation and H1975 xenograft tumor growth (Fig. 5q, r and Supplementary Fig. 7a), concomitant with reduction of total and phosphorylated EGFR protein levels and reduced Ki67+ cells (Supplementary Fig. 7b−d). The gene discussed is FBXL2; the disease is neoplasm.